Literature DB >> 2643020

Medical decision making using the analytic hierarchy process: choice of initial antimicrobial therapy for acute pyelonephritis.

J G Dolan1.   

Abstract

The analytic hierarchy process (AHP) was used to determine which of seven recommended antibiotic regimens represented optimal initial therapy for a young woman hospitalized for treatment of acute pyelonephritis. The model included the following criteria: maximize cure, minimize adverse effects (broken down into very serious, serious, and limited), minimize antibiotic resistance, and minimize cost (divided into total cost and patient cost). The criteria were weighted according to judgments made by 61 practicing clinicians. Alternatives were compared relative to the criteria using published information on the expected frequencies of urinary pathogens and drug toxicity, local antibiotic sensitivities and antibiotic charges, and expert opinion regarding their propensities for inducing antimicrobial resistance. The analysis identified ampicillin combined with gentamicin as the optimal regimen. This study illustrates several features of the AHP that make it promising for use in medical decision making: its ability to incorporate multiple criteria into a formal decision model, its procedural simplicity, and its similarity to current patient management guidelines. Further studies to establish the role of the AHP in medical decision making are warranted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643020     DOI: 10.1177/0272989X8900900109

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  16 in total

1.  Evaluation of ImmunoCard STAT test and ELISA versus light microscopy in diagnosis of giardiasis and cryptosporidiosis.

Authors:  H A Sadaka; M R Gaafar; R F Mady; N N Hezema
Journal:  Parasitol Res       Date:  2015-05-01       Impact factor: 2.289

2.  Cryptosporidiosis: multiattribute evaluation of six diagnostic methods.

Authors:  D W MacPherson; R McQueen
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

3.  Involving patients in complex decisions about their care: an approach using the analytic hierarchy process.

Authors:  J G Dolan; D R Bordley
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

4.  The use of multiattribute decision models in evaluating triptan treatment options in migraine.

Authors:  M D Ferrari; P J Goadsby; R B Lipton; D W Dodick; F M Cutrer; D McCrory; P Williams
Journal:  J Neurol       Date:  2005-03-11       Impact factor: 4.849

5.  Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.

Authors:  M Thill; G Pisa; G Isbary
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-05       Impact factor: 2.915

Review 6.  Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

Authors:  David W Dodick; Richard B Lipton; Michel D Ferrari; Peter J Goadsby; Douglas McCrory; F Michael Cutrer; Paul Williams
Journal:  Curr Pain Headache Rep       Date:  2004-12

7.  Patient priorities in colorectal cancer screening decisions.

Authors:  James G Dolan
Journal:  Health Expect       Date:  2005-12       Impact factor: 3.377

8.  Laboratory utility of coproscopy, copro immunoassays and copro nPCR assay targeting Hsp90 gene for detection of Cryptosporidium in children, Cairo, Egypt.

Authors:  Marwa M I Ghallab; Inas Z Abdel Aziz; Eman Y Shoeib; Ayman A El-Badry
Journal:  J Parasit Dis       Date:  2014-10-30

9.  Methods for Incorporating Patient Preferences for Treatments of Depression in Community Mental Health Settings.

Authors:  Paul Crits-Christoph; Robert Gallop; Caroline K Diehl; Seohyun Yin; Mary Beth Connolly Gibbons
Journal:  Adm Policy Ment Health       Date:  2017-09

Review 10.  Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reporting.

Authors:  Katharina Schmidt; Ines Aumann; Ines Hollander; Kathrin Damm; J-Matthias Graf von der Schulenburg
Journal:  BMC Med Inform Decis Mak       Date:  2015-12-24       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.